[18F]Fluciclovine与[18F]DCFPyL PET/CT在前列腺癌生化复发中的比较
本研究前瞻性比较了[18F]Fluciclovine与[18F]DCFPyL PET/CT在机器人辅助根治性前列腺切除术后生化复发(PSA 0.2-2.0 ng/mL)患者中的检出率。结果显示[18F]DCFPyL总体阳性率显著更高(44% vs 24%,p=0.018),主要体现在盆腔淋巴结转移检出(22% vs 8.0%,p=0.016)。两种示踪剂观察者间一致性均为中等。
要点
- [18F]DCFPyL总体检出率显著高于[18F]Fluciclovine(44% vs 24%,p=0.018)。
- 盆腔淋巴结转移检出率[18F]DCFPyL显著更高(22% vs 8.0%,p=0.016)。
- 两种示踪剂观察者间一致性均为中等(κ=0.59 vs 0.55)。
核心结论
- 在机器人辅助根治性前列腺切除术后低PSA水平(0.2-2.0 ng/mL)生化复发患者中,[18F]DCFPyL在检测盆腔淋巴结转移方面优于[18F]Fluciclovine。
研究设计与样本
- 前瞻性、单中心、单臂、比较影像学试验,50例生化复发患者(PSA 0.2-2.0 ng/mL)在15天内先后接受[18F]Fluciclovine和[18F]DCFPyL PET/CT,由三名盲法核医学专家独立阅片。
主要发现
- 总体扫描阳性率[18F]DCFPyL为44%(22/50),[18F]Fluciclovine为24%(12/50),p=0.018。
- 两种示踪剂局部复发检出率均为16%(8/50)。
- 盆腔淋巴结转移检出率[18F]DCFPyL为22%,[18F]Fluciclovine为8.0%,p=0.016。
- 远处转移检出率[18F]DCFPyL为6.0%,[18F]Fluciclovine为2.0%,p=0.50。
- 观察者间一致性[18F]DCFPyL为κ=0.59,[18F]Fluciclovine为κ=0.55,均为中等。
关键数值与推荐
- 病灶按预设区域(前列腺床、盆腔及盆腔外淋巴结、骨、内脏)分类为阳性或阴性,分歧以多数一致(≥2/3阅片者)共识解决。
- 观察者间一致性采用Fleiss kappa评估。
临床怎么用
- 对于机器人辅助根治性前列腺切除术后低PSA水平生化复发患者,[18F]DCFPyL PET/CT可能有助于更早检出盆腔淋巴结转移并指导个体化挽救治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The current EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines recommend radiolabeled prostate-specific membrane antigen (PSMA), choline, or fluciclovine PET/CT at biochemical recurrence (BCR) of prostate cancer (PCa) after radical prostatectomy. While studies compared [68Ga]Ga-PSMA-11 and [18F]Fluciclovine, data on 18F-labelled PSMA-ligands versus [18F]Fluciclovine in patients with low prostate-specific antigen (PSA) levels (< 2 ng/mL) are limited. This study compared the detection rates of [18F]Fluciclovine and [18F]DCFPyL PET/CT in patients with BCR after robot-assisted radical prostatectomy (RARP). Secondary objectives included stratifying detection rates by PSA level, anatomical regions and assessing inter-observer agreement. METHODS: In this prospective, single-center study, patients with BCR (PSA 0.2-2.0 ng/mL) underwent both [18F]Fluciclovine and [18F]DCFPyL PET/CT within 15 days. Three blinded nuclear medicine experts independently reviewed all scans. Lesions were classified as positive or negative in predefined regions (i.e., prostate bed, pelvic and extra-pelvic lymph nodes, bone, and visceral). Discrepancies were resolved by consensus, defined as majority agreement (≥ 2/3 readers). Inter-observer agreement was assessed using Fleiss’ kappa. RESULTS: Overall scan positivity was 44% (22/50 patients) for [18F]DCFPyL PET/CT and 24% (12/50) for [18F]Fluciclovine PET/CT (p = 0.018). Detection rates increased with rising PSA levels for both tracers. Local recurrence was detected by both tracers in 16% (8/50) of patients. Metastatic disease detection rates for [18F]DCFPyL versus [18F]Fluciclovine were 22% vs. 8.0% for pelvic lymph nodes (p = 0.016), and 6.0% versus 2.0% for distant metastases (p = 0.50), respectively. Inter-observer agreement was moderate for both tracers (κ = 0.59 for [18F]DCFPyL and κ = 0.55 for [18F]Fluciclovine). CONCLUSION: This study demonstrated the superiority of [18F]DCFPyL over [18F]Fluciclovine in detecting pelvic lymph node metastases in patients presenting with BCR after RARP at low PSA levels. These findings suggest the potential of [18F]DCFPyL PET/CT to facilitate earlier and more personalized salvage treatment strategies.
引用
- Luining WI, Vis AN, Donswijk ML, et al. [18F]Fluciclovine PET/CT versus [18F]DCFPyL PET/CT in patients with biochemical recurrence of prostate cancer after robot-assisted radical prostatectomy: a prospective, single-center, single-arm, comparative imaging trial. Eur J Nucl Med Mol Imaging. 2026. PMID: 41762267. doi:10.1007/s00259-026-07816-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。